Scholarlink

<p>The expression of Wnt/β-catenin signaling markers (<i>CTNNB1</i>, <i>LEF1/TCF7</i>, <i>c-myc</i>, <i>cyclinD</i>) was assessed in ascites tumor cells with epithelial (EpCam-CK18-E-cadherin), epithelial–mesenchymal (EpCam-CK18-Vimentin), and epithelial–mesenchymal phenotype with stemness features (EpCam-CK18-Vimentin-CD44-CD133) in patients with advanced ovarian cancer. The expression of <i>CTNNB1</i>, <i>LEF1/TCF7</i>, and <i>cyclinD</i> was significantly increased in cells of the epithelial–mesenchymal phenotype with stemness features in patients with refractory tumor. The duration of the relapse-free period is associated with the level of <i>CTNNB1</i> expression in cells of the epithelial–mesenchymal phenotype with stemness features and the level of <i>LEF1</i> expression in cells of the epithelial–mesenchymal phenotype.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Expression of Wnt/β-Catenin Pathway Markers in Ascites Tumor Cells in Ovarian Cancer

  • 期刊论文

  • 发表日期：

    2025年5月1日

查看全文
  • T. V. Abakumova,
  • D. R. Dolgova,
  • I. I. Antoneeva,
  • T. P. Gening,
  • I. R. Myagdieva,
  • Yu. S. Slesareva

摘要

The expression of Wnt/β-catenin signaling markers (CTNNB1, LEF1/TCF7, c-myc, cyclinD) was assessed in ascites tumor cells with epithelial (EpCam-CK18-E-cadherin), epithelial–mesenchymal (EpCam-CK18-Vimentin), and epithelial–mesenchymal phenotype with stemness features (EpCam-CK18-Vimentin-CD44-CD133) in patients with advanced ovarian cancer. The expression of CTNNB1, LEF1/TCF7, and cyclinD was significantly increased in cells of the epithelial–mesenchymal phenotype with stemness features in patients with refractory tumor. The duration of the relapse-free period is associated with the level of CTNNB1 expression in cells of the epithelial–mesenchymal phenotype with stemness features and the level of LEF1 expression in cells of the epithelial–mesenchymal phenotype.